Breast cancer anti-hormonal therapy and rheumatic diseases: linking the clinical to molecular world
Beyond Rheumatology · 2020
DOI: 10.4081/br.2020.30 ↗Kurz gefasst
Fachartikel in der Zeitschrift Beyond Rheumatology, 2020. Verfasst von Nadia Melillo und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Anti-hormonal therapies are used in the treatment of hormone dependent breast cancer. Their use may be complicated with the onset of arthralgia and autoimmune diseases. Recently a clinical relationship between oestrogen, anti-oestrogen therapy and rheumatic diseases has been reported in the literature, but, until now, experimental supporting data about the interacting biochemical pathways involved are still very limited. The understanding of this molecular link may provide important information to elucidate the relationship between autoimmunity and cancer mechanism and treatment. This review is intended to highlight the relationship between known common molecular mechanisms which explain this association and that probably need to be investigated in future studies.
Zitieren
APA
Melillo, N., & Cantatore, F. P. (2020). Breast cancer anti-hormonal therapy and rheumatic diseases: linking the clinical to molecular world. Beyond Rheumatology. https://doi.org/10.4081/br.2020.30
Vancouver
Melillo N, Cantatore FP. Breast cancer anti-hormonal therapy and rheumatic diseases: linking the clinical to molecular world. Beyond Rheumatology. 2020. doi:10.4081/br.2020.30
BibTeX
@article{Melillo2020,
author = {Melillo, Nadia and Cantatore, Francesco Paolo},
title = {Breast cancer anti-hormonal therapy and rheumatic diseases: linking the clinical to molecular world},
journal = {Beyond Rheumatology},
year = {2020},
doi = {10.4081/br.2020.30}
}
EUVIMED